$ALMS has received discussion from 2 distinct FinTwit voices over the past 12 months, with 3 total mentions concentrated in the biotech category. The first mention appeared on 2026-01-06 at 12:06:49 UTC, with the most recent on the same day at 13:39:45 UTC. Adam Feuerstein (@adamfeuerstein) was the most active voice with 2 mentions, followed by InvestmentGuru (@investmentguru_) with 1 mention.

Discussion centered on Alumis Inc's phase three trial results for envudeucitinib, its drug candidate for moderate-to-severe plaque psoriasis. The stock experienced an 84.26% gain following the announcement that both phase three trials met all primary and secondary endpoints. Voices highlighted specific efficacy metrics, including approximately 65% of patients achieving PASI 90 skin clearance at Week 24 and more than 40% achieving PASI 100, with rapid responses observed as early as Week 4 and superior performance compared to apremilast across PASI endpoints.